CF
RYTM icon

Centaurus Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Centaurus Financial’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Sell
2,314
-75
-3% -$7.29K 0.01% 820
2025
Q4 		$256K Hold
2,389
– – 0.01% 730
2025
Q3 		$241K Buy
+2,389
New +$222K 0.01% 743

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Centaurus Financial's RYTM Position: Q1 2026 in Review

Centaurus Financial reduced its Rhythm Pharmaceuticals (RYTM) stake by 3.1% in Q1 2026, selling an estimated $7.29K and leaving 2,314 shares worth $201K. The position accounts for 0.01% of the portfolio, ranked #820.

Centaurus Financial first reported a position in RYTM in Q3 2025 and has held it in 3 quarters since. The position peaked at $256K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Centaurus Financial held 2,314 shares of Rhythm Pharmaceuticals worth $201K as of Q1 2026.
  • Centaurus Financial sold 75 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $7.29K.
  • Rhythm Pharmaceuticals made up 0.01% of Centaurus Financial's portfolio in Q1 2026, its #820 holding.
  • Centaurus Financial first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Centaurus Financial's Rhythm Pharmaceuticals position peaked at $256K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.